{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:57Z","timestamp":1786982757432,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01058"],"award-info":[{"award-number":["2020-01058"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40264-024-01500-x","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:12:33Z","timestamp":1733958753000},"page":"375-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-9921","authenticated-orcid":false,"given":"Unnur","family":"Gudnadottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Vlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Engstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"1500_CR1","unstructured":"L\u00e4kemedelsverket. L\u00e4kemedel vid graviditet och amning. 2022 December 5th 2019; Available from: https:\/\/www.lakemedelsverket.se\/sv\/behandling-och-forskrivning\/kopa-anvanda-och-hantera\/anvanda-medicin\/graviditet-och-amning#hmainbody1."},{"key":"1500_CR2","unstructured":"NIDA. Are prescription drugs safe to take when pregnant? 2020 June 2020; Available from: https:\/\/nida.nih.gov\/publications\/research-reports\/misuse-prescription-drugs\/are-prescription-drugs-safe-to-take-when-pregnant."},{"issue":"1","key":"1500_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canep.2014.10.008","volume":"39","author":"A Bonaventure","year":"2015","unstructured":"Bonaventure A, et al. Prescription drug use during pregnancy and risk of childhood cancer\u2014is there an association? Cancer Epidemiol. 2015;39(1):73\u20138.","journal-title":"Cancer Epidemiol"},{"issue":"6285","key":"1500_CR4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1126\/science.aad3503","volume":"352","author":"G Falony","year":"2016","unstructured":"Falony G, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560\u20134.","journal-title":"Science"},{"issue":"6285","key":"1500_CR5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova A, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565\u20139.","journal-title":"Science"},{"issue":"5","key":"1500_CR6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.15604","volume":"51","author":"L Macke","year":"2020","unstructured":"Macke L, et al. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51(5):505\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1500_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/biomedicines8110502","volume":"8","author":"T Konstantinidis","year":"2020","unstructured":"Konstantinidis T, et al. Effects of antibiotics upon the gut microbiome: a review of the literature. Biomedicines. 2020;8(11):502.","journal-title":"Biomedicines"},{"issue":"2","key":"1500_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106502","volume":"59","author":"K Nel Van Zyl","year":"2022","unstructured":"Nel Van Zyl K, et al. Effect of antibiotics on the human microbiome: a systematic review. Int J Antimicrob Agents. 2022;59(2): 106502.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1500_CR9","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/apa.15213","volume":"109","author":"EI Levy","year":"2020","unstructured":"Levy EI, Hoang DM, Vandenplas Y. The effects of proton pump inhibitors on the microbiome in young children. Acta Paediatr. 2020;109(8):1531\u20138.","journal-title":"Acta Paediatr"},{"issue":"1","key":"1500_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13099-022-00518-9","volume":"14","author":"N Brusselaers","year":"2022","unstructured":"Brusselaers N, et al. Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort. Gut Pathog. 2022;14(1):47.","journal-title":"Gut Pathog"},{"key":"1500_CR11","doi-asserted-by":"crossref","unstructured":"Sepich-Poore GD et al. The microbiome and human cancer. Science 2021;371(6536).","DOI":"10.1126\/science.abc4552"},{"issue":"3","key":"1500_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.gtc.2019.04.002","volume":"48","author":"N Brusselaers","year":"2019","unstructured":"Brusselaers N. Prescribed drugs and the microbiome. Gastroenterol Clin North Am. 2019;48(3):331\u201342.","journal-title":"Gastroenterol Clin North Am"},{"issue":"5","key":"1500_CR13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740\u20138.","journal-title":"Gut"},{"issue":"4","key":"1500_CR14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/19490976.2017.1284732","volume":"8","author":"F Imhann","year":"2017","unstructured":"Imhann F, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8(4):351\u20138.","journal-title":"Gut Microbes"},{"issue":"10","key":"1500_CR15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/17425255.2021.1974000","volume":"17","author":"W Qu","year":"2021","unstructured":"Qu W, Liu L, Miao L. Exposure to antibiotics during pregnancy alters offspring outcomes. Expert Opin Drug Metab Toxicol. 2021;17(10):1165\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"1500_CR16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/phar.1649","volume":"35","author":"PB Bookstaver","year":"2015","unstructured":"Bookstaver PB, et al. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052\u201362.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1500_CR17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/1471-0528.13601","volume":"123","author":"MB Azad","year":"2016","unstructured":"Azad MB, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG. 2016;123(6):983\u201393.","journal-title":"BJOG"},{"key":"1500_CR18","first-page":"1106","volume":"14","author":"MS Martins Lopes","year":"2020","unstructured":"Martins Lopes MS, et al. Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature. Ecancermedicalscience. 2020;14:1106.","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"1500_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1113\/EP089919","volume":"107","author":"S Ahearn-Ford","year":"2022","unstructured":"Ahearn-Ford S, Berrington JE, Stewart CJ. Development of the gut microbiome in early life. Exp Physiol. 2022;107(5):415\u201321.","journal-title":"Exp Physiol"},{"issue":"6","key":"1500_CR20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/gutjnl-2018-317503","volume":"68","author":"MG Dominguez-Bello","year":"2019","unstructured":"Dominguez-Bello MG, et al. Role of the microbiome in human development. Gut. 2019;68(6):1108\u201314.","journal-title":"Gut"},{"issue":"5","key":"1500_CR21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkac053","volume":"77","author":"MH Nguyen","year":"2022","unstructured":"Nguyen MH, et al. Antibiotic use during pregnancy and the risk of preterm birth: a population-based Swedish cohort study. J Antimicrob Chemother. 2022;77(5):1461\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1500_CR22","volume":"89","author":"SA Orwa","year":"2023","unstructured":"Orwa SA, Gudnadottir U, Brusselaers N. Global prevalence of antibiotic consumption during pregnancy: a systematic review and meta-analysis. Under Rev. 2023;89(2): 106189.","journal-title":"Under Rev"},{"issue":"23","key":"1500_CR23","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.3390\/ijerph182312621","volume":"18","author":"A Cantarutti","year":"2021","unstructured":"Cantarutti A, et al. Use of antibiotic treatment in pregnancy and the risk of several neonatal outcomes: a population-based study. Int J Environ Res Public Health. 2021;18(23):12621.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1500_CR24","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1067\/mob.2002.122598","volume":"186","author":"KL Koch","year":"2002","unstructured":"Koch KL. Gastrointestinal factors in nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5):S198\u2013203.","journal-title":"Am J Obstet Gynecol"},{"issue":"13","key":"1500_CR25","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jama.2016.14337","volume":"316","author":"C McParlin","year":"2016","unstructured":"McParlin C, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA. 2016;316(13):1392\u2013401.","journal-title":"JAMA"},{"key":"1500_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CLEP.S16305","volume":"3","author":"O Stephansson","year":"2011","unstructured":"Stephansson O, et al. Drug use during pregnancy in Sweden\u2014assessed by the prescribed drug register and the medical birth register. Clin Epidemiol. 2011;3:43\u201350.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"1500_CR27","first-page":"273","volume":"66","author":"BT Vanderhoff","year":"2002","unstructured":"Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273\u201380.","journal-title":"Am Fam Physician"},{"issue":"4","key":"1500_CR28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/apt.15610","volume":"51","author":"CM Li","year":"2020","unstructured":"Li CM, et al. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. Aliment Pharmacol Ther. 2020;51(4):410\u201320.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1500_CR29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12916-022-02673-x","volume":"20","author":"EM Breddels","year":"2022","unstructured":"Breddels EM, et al. Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events. BMC Med. 2022;20(1):492.","journal-title":"BMC Med"},{"key":"1500_CR30","doi-asserted-by":"crossref","unstructured":"Ngwenya S, Simin J and Brusselaers N. Maintenance proton pump inhibitor use associated with increased all-cause and cause-specific mortality in Sweden. Dig Dis Sci. 2023.","DOI":"10.1007\/s10620-023-07820-9"},{"key":"1500_CR31","volume":"365","author":"Y Xie","year":"2019","unstructured":"Xie Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365: l1580.","journal-title":"BMJ"},{"issue":"4","key":"1500_CR32","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/j.cgh.2021.01.014","volume":"20","author":"SH Baik","year":"2022","unstructured":"Baik SH, Fung KW, McDonald CJ. The mortality risk of proton pump inhibitors in 1.9 million US seniors: an extended Cox survival analysis. Clin Gastroenterol Hepatol. 2022;20(4):e671\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1500_CR33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.651","volume":"8","author":"M Ben-Eltriki","year":"2020","unstructured":"Ben-Eltriki M, et al. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect. 2020;8(5): e00651.","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"1500_CR34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ajhp\/zxad009","volume":"80","author":"KM Thurber","year":"2023","unstructured":"Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm. 2023;80(8):487\u201394.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1500_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","volume":"15","author":"RM Ward","year":"2013","unstructured":"Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013;15(2):119\u201331.","journal-title":"Paediatr Drugs"},{"issue":"12","key":"1500_CR36","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41416-020-01082-2","volume":"123","author":"J Simin","year":"2020","unstructured":"Simin J, et al. Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis. Br J Cancer. 2020;123(12):1825\u201332.","journal-title":"Br J Cancer"},{"key":"1500_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105072","volume":"160","author":"J Simin","year":"2020","unstructured":"Simin J, et al. Antibiotic use and the risk of breast cancer: a systematic review and dose-response meta-analysis. Pharmacol Res. 2020;160: 105072.","journal-title":"Pharmacol Res"},{"key":"1500_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101585","volume":"62","author":"N Brusselaers","year":"2019","unstructured":"Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019;62: 101585.","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"1500_CR39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017739","volume":"7","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10): e017739.","journal-title":"BMJ Open"},{"issue":"4","key":"1500_CR40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00535-019-01652-z","volume":"55","author":"N Brusselaers","year":"2020","unstructured":"Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55(4):453\u201361.","journal-title":"J Gastroenterol"},{"issue":"4","key":"1500_CR41","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/hep.31914","volume":"74","author":"H Kamal","year":"2021","unstructured":"Kamal H, et al. Association between proton pump inhibitor use and biliary tract cancer risk: a Swedish population-based cohort study. Hepatology. 2021;74(4):2021\u201331.","journal-title":"Hepatology"},{"issue":"1","key":"1500_CR42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","volume":"71","author":"D Abrahami","year":"2022","unstructured":"Abrahami D, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16\u201324.","journal-title":"Gut"},{"issue":"11","key":"1500_CR43","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1136\/gutjnl-2020-323845","volume":"70","author":"SI Seo","year":"2021","unstructured":"Seo SI, et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. 2021;70(11):2066\u201375.","journal-title":"Gut"},{"key":"1500_CR44","doi-asserted-by":"crossref","first-page":"175628482110514","DOI":"10.1177\/17562848211051463","volume":"14","author":"D Segna","year":"2021","unstructured":"Segna D, et al. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211051464.","journal-title":"Therap Adv Gastroenterol"},{"issue":"16","key":"1500_CR45","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3748\/wjg.v19.i16.2560","volume":"19","author":"JS Ahn","year":"2013","unstructured":"Ahn JS, et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19(16):2560\u20138.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1500_CR46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10147-022-02253-2","volume":"28","author":"TR Peng","year":"2023","unstructured":"Peng TR, Wu TW, Li CH. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2023;28(1):99\u2013109.","journal-title":"Int J Clin Oncol"},{"key":"1500_CR47","doi-asserted-by":"crossref","first-page":"1129948","DOI":"10.3389\/fphar.2023.1129948","volume":"14","author":"H Guo","year":"2023","unstructured":"Guo H, et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1129948.","journal-title":"Front Pharmacol"},{"key":"1500_CR48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.07.030","volume":"156","author":"R Zeng","year":"2021","unstructured":"Zeng R, et al. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer. 2021;156:190\u2013201.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1500_CR49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pedhc.2021.05.005","volume":"36","author":"JM Buser","year":"2022","unstructured":"Buser JM, Lake K, Ginier E. Environmental risk factors for childhood cancer in an era of global climate change: a scoping review. J Pediatr Health Care. 2022;36(1):46\u201356.","journal-title":"J Pediatr Health Care"},{"key":"1500_CR50","unstructured":"(WHO), W.H.O. Childhood cancer. 2021; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer-in-children."},{"issue":"8","key":"1500_CR51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10552-010-9561-2","volume":"21","author":"P Kaatsch","year":"2010","unstructured":"Kaatsch P, Scheidemann-Wesp U, Schuz J. Maternal use of antibiotics and cancer in the offspring: results of a case-control study in Germany. Cancer Causes Control. 2010;21(8):1335\u201345.","journal-title":"Cancer Causes Control"},{"issue":"11","key":"1500_CR52","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1002\/cam4.2412","volume":"8","author":"X Ye","year":"2019","unstructured":"Ye X, et al. Maternal use of antibiotics and cancer incidence risk in offspring: a population-based cohort study in Manitoba, Canada. Cancer Med. 2019;8(11):5367\u201372.","journal-title":"Cancer Med"},{"issue":"5","key":"1500_CR53","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/ije\/dyad004","volume":"52","author":"CC Murphy","year":"2023","unstructured":"Murphy CC, et al. In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18,000 adult offspring. Int J Epidemiol. 2023;52(5):1448\u201358.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"1500_CR54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.canep.2010.04.018","volume":"34","author":"K Stalberg","year":"2010","unstructured":"Stalberg K, et al. Prenatal exposure to medicines and the risk of childhood brain tumor. Cancer Epidemiol. 2010;34(4):400\u20134.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"1500_CR55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ije\/dyab219","volume":"51","author":"S Hjorth","year":"2022","unstructured":"Hjorth S, et al. Prenatal exposure to nitrofurantoin and risk of childhood leukaemia: a registry-based cohort study in four Nordic countries. Int J Epidemiol. 2022;51(3):778\u201388.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"1500_CR56","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/(SICI)1097-0142(19981001)83:7<1461::AID-CNCR25>3.0.CO;2-1","volume":"83","author":"PB Thapa","year":"1998","unstructured":"Thapa PB, et al. Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer. 1998;83(7):1461\u20138.","journal-title":"Cancer"},{"issue":"8","key":"1500_CR57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/pds.3806","volume":"24","author":"NC Momen","year":"2015","unstructured":"Momen NC, et al. Exposure to systemic antibacterial medications during pregnancy and risk of childhood cancer. Pharmacoepidemiol Drug Saf. 2015;24(8):821\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1500_CR58","unstructured":"Epidemiology, C.f. The swedish medical birth register, S.N.B.o.H.a. Welfare, Editor. 2003. Centre for Epidemiology"},{"key":"1500_CR59","unstructured":"Socialstyrelsen. National Patient Register. 2022; Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-patient-register\/."},{"issue":"9","key":"1500_CR60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765\u201373.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"1500_CR61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, et al. The new Swedish prescribed drug register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1500_CR62","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1500_CR63","unstructured":"Methodology, W.C.C.f.D.S. ATC\/DDD Index 2022. 2021; Available from: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"1500_CR64","unstructured":"Socialstyrelsen, Klassifikation av sjukdomar och h\u00e4lsoproblem 1997, Socialstyrelsen, Editor. 1996."},{"key":"1500_CR65","unstructured":"National Cancer Institute. ICCC recode third edition ICD-O-3\/IARC 20171. 2017; Available from: https:\/\/seer.cancer.gov\/iccc\/iccc-iarc-2017.html."},{"issue":"1","key":"1500_CR66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12958-022-00905-6","volume":"20","author":"R Fornes","year":"2022","unstructured":"Fornes R, et al. Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. Reprod Biol Endocrinol. 2022;20(1):30.","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"1500_CR67","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12519-020-00338-4","volume":"16","author":"LL Jiang","year":"2020","unstructured":"Jiang LL, et al. Cesarean section and risk of childhood leukemia: a systematic review and meta-analysis. World J Pediatr. 2020;16(5):471\u20139.","journal-title":"World J Pediatr"},{"issue":"4","key":"1500_CR68","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41571-020-00445-1","volume":"18","author":"N Akimoto","year":"2021","unstructured":"Akimoto N, et al. Rising incidence of early-onset colorectal cancer\u2014a call to action. Nat Rev Clin Oncol. 2021;18(4):230\u201343.","journal-title":"Nat Rev Clin Oncol"},{"key":"1500_CR69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/5584_2018_312","volume":"1125","author":"M Selma-Royo","year":"2019","unstructured":"Selma-Royo M, et al. Shaping microbiota during the first 1000 days of life. Adv Exp Med Biol. 2019;1125:3\u201324.","journal-title":"Adv Exp Med Biol"},{"key":"1500_CR70","unstructured":"National Institute for Health and Core Excellence (NICE). Gastro-oesophageal reflux disease in children and young people: diagnosis and management. 2015. https:\/\/www.nice.org.uk\/guidance\/ng1."},{"issue":"11","key":"1500_CR71","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029047","volume":"103","author":"S Wang","year":"2024","unstructured":"Wang S, et al. Causal analysis of gastroesophageal reflux disease and esophageal cancer. Medicine (Baltimore). 2024;103(11): e37433.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1500_CR72","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/MPG.0000000000001401","volume":"63","author":"U Krishnan","year":"2016","unstructured":"Krishnan U, et al. ESPGHAN-NASPGHAN guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with esophageal atresia-tracheoesophageal fistula. J Pediatr Gastroenterol Nutr. 2016;63(5):550\u201370.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"1500_CR73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jpn3.12115","volume":"78","author":"G Dimitrov","year":"2024","unstructured":"Dimitrov G, et al. Proton pump inhibitors in esophageal atresia: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr. 2024;78(3):457\u201370.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1500_CR74","volume":"13","author":"V Dipasquale","year":"2022","unstructured":"Dipasquale V, et al. A narrative review on efficacy and safety of proton pump inhibitors in children. Front Pharmacol. 2022;13: 839972.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1500_CR75","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamapediatrics.2023.2900","volume":"177","author":"M Lassalle","year":"2023","unstructured":"Lassalle M, Zureik M, Dray-Spira R. Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatr. 2023;177(10):1028\u201338.","journal-title":"JAMA Pediatr"},{"issue":"6","key":"1500_CR76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cpt.2736","volume":"112","author":"TM van der Zanden","year":"2022","unstructured":"van der Zanden TM, et al. Off-label, but on-evidence? A review of the level of evidence for pediatric pharmacotherapy. Clin Pharmacol Ther. 2022;112(6):1243\u201353.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1500_CR77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00228-008-0560-0","volume":"65","author":"G Tafuri","year":"2009","unstructured":"Tafuri G, et al. Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol. 2009;65(2):209\u201316.","journal-title":"Eur J Clin Pharmacol"},{"key":"1500_CR78","doi-asserted-by":"crossref","unstructured":"Brusselaers N, G U, Engstrand L, Lilja H E. Trends in proton pump inhibitor use in Sweden by sex and age - a drug utilisation study. Drug Safety, In revision, 2024.","DOI":"10.1007\/s40264-024-01502-9"},{"issue":"5","key":"1500_CR79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.aogh.2014.09.013","volume":"80","author":"JK Oh","year":"2014","unstructured":"Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80(5):384\u201392.","journal-title":"Ann Glob Health"},{"issue":"35","key":"1500_CR80","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030487","volume":"101","author":"M Altuwaijri","year":"2022","unstructured":"Altuwaijri M. Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy: a review. Medicine (Baltimore). 2022;101(35): e30487.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"1500_CR81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-020-00926-4","volume":"20","author":"EA Pasman","year":"2020","unstructured":"Pasman EA, et al. Proton pump inhibitors in children: the good, the bad, and the ugly. Curr Allergy Asthma Rep. 2020;20(8):39.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"1500_CR82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/archdischild-2017-314026","volume":"103","author":"P De Bruyne","year":"2018","unstructured":"De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child. 2018;103(1):78\u201382.","journal-title":"Arch Dis Child"},{"issue":"4","key":"1500_CR83","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/MPG.0b013e3181b7f563","volume":"49","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498\u2013547.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"1500_CR84","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/apa.16491","volume":"111","author":"M Lyamouri","year":"2022","unstructured":"Lyamouri M, et al. Proton pump inhibitors for infants in three scandinavian countries increased from 2007 to 2020 despite international recommendations. Acta Paediatr. 2022;111(11):2222\u20138.","journal-title":"Acta Paediatr"},{"issue":"10","key":"1500_CR85","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jpedsurg.2023.05.024","volume":"58","author":"T Wyllie","year":"2023","unstructured":"Wyllie T, et al. Prophylactic acid-suppression medication to prevent anastomotic strictures after oesophageal atresia surgery: a systematic review and meta-analysis. J Pediatr Surg. 2023;58(10):1954\u201362.","journal-title":"J Pediatr Surg"},{"issue":"7402","key":"1500_CR86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11209","volume":"486","author":"Human Microbiome Project, C","year":"2012","unstructured":"Human Microbiome Project, C. A framework for human microbiome research. Nature. 2012;486(7402):215\u201321.","journal-title":"Nature"},{"issue":"1","key":"1500_CR87","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-023-38156-7","volume":"14","author":"M Stocker","year":"2023","unstructured":"Stocker M, et al. Less is more: antibiotics at the beginning of life. Nat Commun. 2023;14(1):2423.","journal-title":"Nat Commun"},{"key":"1500_CR88","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058330","author":"ER Wolf","year":"2023","unstructured":"Wolf ER, et al. Overuse of reflux medications in infants. Pediatrics. 2023. https:\/\/doi.org\/10.1542\/peds.2022-058330.","journal-title":"Pediatrics"},{"issue":"4","key":"1500_CR89","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.arcped.2022.02.004","volume":"29","author":"A Arnoux","year":"2022","unstructured":"Arnoux A, et al. Proton pump inhibitors are still overprescribed for hospitalized children. Arch Pediatr. 2022;29(4):258\u201362.","journal-title":"Arch Pediatr"},{"key":"1500_CR90","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102472","volume":"87","author":"HT Orimoloye","year":"2023","unstructured":"Orimoloye HT, et al. Hyperemesis gravidarum and the risk of childhood cancer\u2014a case-control study in Denmark. Cancer Epidemiol. 2023;87: 102472.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"1500_CR91","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ppul.26817","volume":"59","author":"G Hazan","year":"2024","unstructured":"Hazan G, et al. The impact of maternal hyperemesis gravidarum on early childhood respiratory morbidity. Pediatr Pulmonol. 2024;59(3):707\u201314.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"1500_CR92","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12884-024-06293-6","volume":"24","author":"J Fan","year":"2024","unstructured":"Fan J, Yin M. Offspring of women with hyperemesis gravidarum are more likely to have cardiovascular abnormalities. BMC Pregnancy Childbirth. 2024;24(1):119.","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01500-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01500-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01500-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T18:49:22Z","timestamp":1741805362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01500-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01500-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"14 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Karolinska Institute. This work was supported by funding from the Swedish Research Council (2020-01058).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data are located on an access-controlled server at Karolinska Institutet and is not openly available due to the sensitive personal nature of it.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"This study was approved by the Regional Ethics Committee of Stockholm (2017\/2423-31) and was conducted according to the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was not required for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Code used for data analysis is available upon a reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization (U.G., E.F. and N.B.), methodology (U.G., G.L. and N.B.), software (U.G. and N.B.), validation (U.G. and N.B.), formal analysis (U.G. under supervision of N.B.), investigation (U.G. and N.B.), resources (E.F., L.E. and N.B.), data curation (U.G. and N.B.), writing\u2014original draft (U.G., E.F. and N.B.), writing\u2014review and editing (U.G., E.F., G.L., A.W., E.V., L.E. and N.B.), visualization (U.G.), supervision (E.F. and N.B.), project administration (E.F., L.E. and N.B.) and funding acquisition (E.F., L.E. and N.B.). All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}